OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis → Prepare for a recession unlike any other (From American Hartford Gold Group) (Ad) Free BPMUF Stock Alerts $44.45 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$44.45▼$44.4550-Day Range$40.75▼$44.4552-Week Range$38.60▼$44.45VolumeN/AAverage Volume5 shsMarket Capitalization$526.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Basilea Pharmaceutica alerts: Email Address Ad American Hartford Gold GroupPrepare for a recession unlike any otherThese 42 powerful nations just launched the first-ever “Anti-Dollar Alliance”… And together, they plan to KILL the greenback and DETHRONE America once and for all. Leading the charge are the usual suspects: Russia, China, Iran, oil-soaked Saudi Arabia, and even our neighbor, Mexico. And because this alliance holds close to 70% of all US Dollars… Ditching their holdings could flood America with a tsunami of US Dollars… Triggering hyper-inflation and a Wall Street nosedive so deep, it VAPORIZES trillions in hard-earned retirement savings.GET THE FREE GUIDE About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Read More BPMUF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMUF Stock News HeadlinesApril 24, 2024 | finance.yahoo.comBasilea shareholders approve all proposals of the board of directors at the annual general meetingApril 24, 2024 | finance.yahoo.comBasilea Pharmaceutica AG (0QNA.L)April 25, 2024 | American Hartford Gold Group (Ad)Prepare for a recession unlike any otherThese 42 powerful nations just launched the first-ever “Anti-Dollar Alliance”… And together, they plan to KILL the greenback and DETHRONE America once and for all. Leading the charge are the usual suspects: Russia, China, Iran, oil-soaked Saudi Arabia, and even our neighbor, Mexico. And because this alliance holds close to 70% of all US Dollars… Ditching their holdings could flood America with a tsunami of US Dollars… Triggering hyper-inflation and a Wall Street nosedive so deep, it VAPORIZES trillions in hard-earned retirement savings.April 9, 2024 | finance.yahoo.comBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsApril 4, 2024 | msn.comUPDATE 2-US FDA approves Basilea Pharmaceutica's antibioticApril 4, 2024 | msn.comEuropean stocks rise ahead of inflation data; Basilea shinesApril 4, 2024 | finance.yahoo.comBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsApril 3, 2024 | reuters.comUS FDA approves Basilea Pharmaceutica's antibioticApril 25, 2024 | American Hartford Gold Group (Ad)Prepare for a recession unlike any otherThese 42 powerful nations just launched the first-ever “Anti-Dollar Alliance”… And together, they plan to KILL the greenback and DETHRONE America once and for all. Leading the charge are the usual suspects: Russia, China, Iran, oil-soaked Saudi Arabia, and even our neighbor, Mexico. And because this alliance holds close to 70% of all US Dollars… Ditching their holdings could flood America with a tsunami of US Dollars… Triggering hyper-inflation and a Wall Street nosedive so deep, it VAPORIZES trillions in hard-earned retirement savings.March 11, 2024 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaFebruary 21, 2024 | investing.comBasilea Pharmaceutica AG (BSLN)February 13, 2024 | finance.yahoo.comBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioJanuary 19, 2024 | finance.yahoo.comCresemba® sales in Latin America trigger first sales milestone payment to BasileaJanuary 15, 2024 | markets.businessinsider.comBasilea To Buy Preclinical Antibiotics Program From SpexisJanuary 15, 2024 | finance.yahoo.comBasilea announces acquisition of preclinical antibiotics program from SpexisJanuary 5, 2024 | finance.yahoo.comBasilea provides portfolio status updateDecember 20, 2023 | markets.businessinsider.comBasilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured LoanDecember 20, 2023 | finance.yahoo.comBasilea announces accelerated loan repaymentDecember 11, 2023 | finance.yahoo.comBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisDecember 4, 2023 | finance.yahoo.comBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsNovember 20, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearNovember 13, 2023 | msn.comPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalNovember 13, 2023 | finance.yahoo.comBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalOctober 31, 2023 | finance.yahoo.comBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentOctober 19, 2023 | finance.yahoo.comBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infectionsOctober 17, 2023 | finance.yahoo.comBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023October 2, 2023 | finance.yahoo.comBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiproleSee More Headlines Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:BPMUF CUSIPN/A CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees147Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.20 Quick Ratio2.64 Sales & Book Value Annual Sales$175.50 million Price / Sales3.00 Cash Flow$1.13 per share Price / Cash Flow39.34 Book Value($0.94) per share Price / Book-47.29Miscellaneous Outstanding Shares11,850,000Free FloatN/AMarket Cap$526.73 million OptionableNot Optionable Beta0.65 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. David Veitch (Age 59)Chief Executive Officer Comp: $1.24MMr. Adesh Kaul (Age 50)Chief Financial Officer Dr. Gerrit Hauck Ph.D. (Age 60)Chief Technology Officer Dr. Laurenz Kellenberger Ph.D. (Age 57)Chief Scientific Officer Dr. Marc Engelhardt M.D. (Age 60)Chief Medical Officer Dr. Peer Nils SchroderHead of Corporate Communications & Investor RelationsMr. Damian Heller (Age 58)General Counsel & Corporate Secretary Mr. Andreas KuminHead of Corporate DevelopmentMs. Ursula Eberhardt (Age 62)Head of Global Human Resources Mr. Mark Jones (Age 56)Head of Project Management & Preclinical Development More ExecutivesKey CompetitorsArriVent BioPharmaNASDAQ:AVBPAstria TherapeuticsNASDAQ:ATXSPhathom PharmaceuticalsNASDAQ:PHATStoke TherapeuticsNASDAQ:STOKAltimmuneNASDAQ:ALTView All Competitors BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed in 2024? Basilea Pharmaceutica's stock was trading at $41.00 at the beginning of 2024. Since then, BPMUF stock has increased by 8.4% and is now trading at $44.45. View the best growth stocks for 2024 here. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Basilea Pharmaceutica have any subsidiaries? The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.Read More This page (OTCMKTS:BPMUF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
